A carregar...
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(...
Na minha lista:
| Publicado no: | Neurol Med Chir (Tokyo) |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Japan Neurosurgical Society
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5243161/ https://ncbi.nlm.nih.gov/pubmed/27725524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2176/nmc.oa.2016-0162 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|